Matinas BioPharma (NYSEAMERICAN:MTNB – Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.02) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.02), Zacks reports.
Matinas BioPharma Price Performance
Matinas BioPharma stock opened at $0.14 on Friday. The stock has a market cap of $35.09 million, a P/E ratio of -1.17 and a beta of 1.70. Matinas BioPharma has a 52 week low of $0.12 and a 52 week high of $0.89.
About Matinas BioPharma
Read More
- Five stocks we like better than Matinas BioPharma
- What Are Growth Stocks and Investing in Them
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- 3 REITs to Buy and Hold for the Long Term
- MarketBeat Week in Review – 8/12 – 8/16
- What Are Dividend Contenders? Investing in Dividend Contenders
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.